Metabolic
Tirzepatide
The first dual GIP/GLP-1 receptor agonist. Eli Lilly's tirzepatide produced superior weight loss to semaglutide in the head-to-head SURMOUNT-5 trial (20.2% vs 13.7%), making it the most effective peptide weight-loss drug currently approved.
Reviewed by Marko Maal, MSc Pharmacy · University of Tartu · Pharmaceutical sciences — drug sourcing, formulation, regulatory review · Reviewed May 6, 2026
Reviewed for clinical and pharmacological accuracy by Marko Maal, MSc Pharmacy.
Common doses
| Indication | Route | Dose | Duration | Evidence |
|---|---|---|---|---|
| Type 2 diabetes | SC injection (Mounjaro) | 2.5 mg → titrate to 5–15 mg weekly | Indefinite | Tier 1 |
| Chronic weight management | SC injection (Zepbound) | 2.5 mg → titrate to 5–15 mg weekly | Indefinite (relapse on cessation) | Tier 1 |
| Obstructive sleep apnea | SC injection (Zepbound) | 10–15 mg weekly | Indefinite | Tier 1 |
Overview
Evidence tier: 5 — editorial framing of the peptide-page entity context.
Tirzepatide is the first commercially approved dual GIP/GLP-1 receptor agonist. Where semaglutide activates only the GLP-1 incretin pathway, tirzepatide activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) — and the addition of GIP signaling appears to translate into measurably superior weight-loss and metabolic effects. Eli Lilly's molecule was FDA-approved as Mounjaro for type 2 diabetes in May 2022, as Zepbound for chronic weight management in November 2023, and as Zepbound for obstructive sleep apnea in December 2024.
The dual mechanism produces unusually strong head-to-head data. SURMOUNT-5 (2025) compared tirzepatide and semaglutide directly in adults with obesity: 20.2% mean weight loss with tirzepatide vs 13.7% with semaglutide. SURPASS-2 had earlier shown tirzepatide superiority for HbA1c and weight in type 2 diabetes. By any reasonable measure, tirzepatide is the most effective peptide weight-loss drug currently approved.
How it works
Evidence tier: 2 — mechanism documented in published pharmacology literature.
GLP-1 receptor activation is the foundation — the same appetite suppression, glucose-dependent insulin enhancement, and slowed gastric emptying that drive semaglutide's effects. GIP receptor activation adds additional benefit through pathways that are still being characterized: more efficient nutrient partitioning, additional appetite-suppression signaling in the brain, and possibly direct effects on adipose tissue lipid metabolism.
Pharmacokinetically, tirzepatide has a 5-day half-life — slightly shorter than semaglutide's 7 days — but still well-suited to once-weekly dosing. The long half-life is achieved through a fatty-acid side chain that allows reversible albumin binding, the same engineering trick used in semaglutide.
Side effects, risks, and practical use
Evidence tier: 3 — clinical case-series + animal-model adverse-event data; magnitude varies by molecule.
Side-effect profile is similar to semaglutide but generally more pronounced — the GI symptoms (nausea, vomiting, diarrhea) tend to be more intense during titration. About 5–10% of patients discontinue due to GI intolerance. Same black-box warning for thyroid C-cell tumors based on rodent data; same contraindication in personal or family history of medullary thyroid carcinoma or MEN 2. Same risk of acute pancreatitis. Same dependence on continued use to maintain weight loss.
Practical considerations:
- Cost. Branded Zepbound is $1,000–1,300/month without insurance. Compounded versions exist in a legally contested zone. The forthcoming oral GIP/GLP-1 orforglipron (Foundayo) launched at $25/month in April 2026 and will rapidly reshape the market.
- Dosing. Standard weekly titration: 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg. Not every patient needs the maximum; many achieve sufficient effect at 5–10 mg.
- Switching from semaglutide. Common in clinical practice when semaglutide-mediated weight loss plateaus. Re-titration is required.
- Discontinuation. Same weight-regain dynamic as semaglutide. Discontinuation is not "stopping a diet"; it is removing an appetite-suppressing drug, with the predictable physiology that follows.
Trial readouts that matter
Evidence tier: 2 — references summarized in the body; see Trial readouts section below for primary-source detail.
SURMOUNT-1 (Jastreboff 2022, NEJM, PMID 35658024) established 22.5% mean weight loss at the 15 mg dose over 72 weeks in adults with obesity but without type 2 diabetes — substantially higher than any prior monotherapy. SURMOUNT-5 (Aronne 2025, NEJM, PMID 40353578) is the head-to-head against semaglutide: tirzepatide produced 20.2% loss vs semaglutide's 13.7% over 72 weeks, with similar discontinuation rates. SURPASS-2 (Frias 2021, NEJM) established the HbA1c advantage in type 2 diabetes vs semaglutide 1 mg.
The December 2024 FDA approval of tirzepatide for obstructive sleep apnea (the SURMOUNT-OSA trials) was the first GLP-1-class approval for OSA, mediated by weight loss but with regulatory implications for insurance coverage. The cardiovascular outcomes program (SURPASS-CVOT) is the major outstanding readout — expected 2026-2027.
Where to go from here
Evidence tier: 5 — editorial framing of the peptide-page entity context.
For the broader Weight Loss pillar including the older AOD-9604 fragment peptides and the emerging oral GLP-1s, see the goal-based hub. For the head-to-head comparison with semaglutide, see /compare/semaglutide-vs-tirzepatide. For per-state legal and access considerations, see the legal status guide.
Related on Peptide Story
- Weight Loss pillar — GLP-1 / GIP class context
- Retatrutide vs Tirzepatide — comparison
- Semaglutide vs Tirzepatide — SURMOUNT-5
References
Limitations · Who should NOT use this
Same side-effect profile as semaglutide but generally more pronounced — GI symptoms (nausea, vomiting, diarrhea) are more common during titration. Black-box warning for thyroid C-cell tumors. Contraindicated in personal or family history of medullary thyroid carcinoma or MEN 2. Risk of acute pancreatitis. Significantly more expensive than semaglutide branded ($1,000–1,300/month). Discontinuation results in weight regain.
Regulatory notes
FDA-approved for type 2 diabetes (Mounjaro, May 2022), chronic weight management (Zepbound, November 2023), and obstructive sleep apnea (December 2024). Eli Lilly's oral GIP/GLP-1, orforglipron (Foundayo), received FDA approval April 2026 at $25/month — fundamentally restructuring the affordability landscape.
Sources
- Jastreboff AM, et al. SURMOUNT-1: NEJM 2022;387(3):205-216.
- Frias JP, et al. SURPASS-2 (vs semaglutide for diabetes): NEJM 2021;385(6):503-515.
- Aronne LJ, et al. SURMOUNT-5 (vs semaglutide for weight): NEJM 2025.
- Malhotra A, et al. SURMOUNT-OSA: NEJM 2024.
Community signal — Tirzepatide
Recent posts and videos mentioning Tirzepatide from the cron-ingested Reddit + Bluesky pipelines and the curated /experts directory. Not endorsement — directional context only.
- r/Retatrutide· u/slovakembassy · 7h ago
should I try tirzepatide instead?
I've been taking reta for 5 months now, on and off. For the first few months it was consistent weekly, then I've taken breaks when the symptoms got too bad. I've comprehensively experimented between 2-5mg doses after having gotten my body used to it at the start. Consistently, I experience increased food noise than before reta, mainly for sugary foods, but also just never feeling full for long. I experimented taking 5mg and that had me unable to eat anything, but then my body adjusted and the food noise immediately came back. The issue with this is that I thought I was supposed to save money on food on a GLP 1, but am now spending even more lol. The most disruptive thing about it is my bad sleep- I wake up more times in the night than usual and always awaken between 5-6am and can't fall back asleep, regardless of how exhausted I am. Another two side effects I have are constant diarrhea and also alcohol doesn't work AT ALL. However, on it, and even when I haven't taken it for weeks, I am able to maintain a low weight I couldn't even achieve when I was doing OMAD and carnivore or keto and looked 'snatched'. That's fucking awesome lol... That's why I will never go above 4mg now, cos the nausea and not being able to eat (not to mention the expense of buying so many vials) seems to have no purposes if I can eat all the cake in the world and still be a size 2. Anyone with experience with both tirz and reta and has had similar symptoms on reta able to give me any pointers? Thanksss   submitted by   /u/slovakembassy [link]   [comments]
- r/Semaglutide· u/a901501 · 7h ago
VLS tirzepatide 20 mg
Has anyone got any experience using this pen? I purchased through a friend who had been using. I want to know if anyone else has any experience with this pen? I’ve verified it on the website.   submitted by   /u/a901501 [link]   [comments]
- r/Mounjaro· u/Straight_Win_5613 · 11h ago
THANK YOU!
This kind of relates to insurance and healthcare providers both. But I’ve been in this sub since 2022. I started on Mounjaro at the end of September 2022, as a recommendation from my PCP. We ran into coupon issues and my PCP kind of shrugged at me, not really wanting to help, I get it, it is a pain in the butt and more work for them. I hustled and I used that coupon for all it was worth! Even having to travel outside my little town. I kind of did everything backwards, though I realized this worked and then went to an endocrinologist and an OB/GYN. They were both pretty helpful, but could never get this covered for me. I had given up and convinced myself that I was just going to have to buy Zepbound out-of-pocket from Lilly Direct and I did for about a year. But finances are so super tight, and after 100 pounds fine, I decided to try one more time. I finally saw a metabolic doctor. She dived deeper into absolutely everything. My PCP just poo pooed a fasting glucose of 140 that I had. She said it was just a one off no curiosity at all because my A1c was OK, just borderline. I learned a lot about A1c and that it isn’t the only indicator of insulin resistance and a lot of that was through this sub. So combing through medical history, years of labs, trying to get records from the military (almost impossible) as a 23 year old never thought I would need them! And a lot of research through this sub and other sources. I am FINALLY approved! It’s just a one year PA, but one YEAR is such a miracle for me! I thought I would be denied, have to fight, go through all appeals processes,etc. etc. but literally hours after she submitted I received an approval notice, got it filled and picked it up for a $25 copay. I cried multiple times today! So all of this to say thank you for all information and help in here AND advocate for yourself, no one else will sometimes. It’s been super hard for me to do. I have an overactive sense of loyalty and felt like I was going behind the back of my PCP, we don’t have to have referrals for specialists. But I have to say, going from $450 a fill to $25 a month is totally worth it! No guilt.   submitted by   /u/Straight_Win_5613 [link]   [comments]
No Bluesky posts mentioning Tirzepatide in our index yet — the Bluesky cron pulls every four hours.
No curated experts have Tirzepatide tagged in their peptideAreas yet.
No YouTube videos mentioning Tirzepatide in our index yet. The YouTube RSS cron pulls every 6 hours.
Community Notes
0 approved · moderated
Structured notes from readers — context, citations, corrections, and first-hand experience. Every note is moderated before it appears. Notes do not replace medical review; they supplement it.
No approved notes yet.
Know something that should be on this page? A citation, clarification, or dispute? Sign in and submit the first note.
Submission interface coming in Phase 2. For now, notes are authored in Studio. See the Community Guidelines for moderation criteria.